Anatomic Stage II Breast Cancer AJCC v8 Clinical Trials

40 studies are recruiting for anatomic stage ii breast cancer ajcc v8 in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Breast Cancer Survivorship Biorepository

   This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer…

   Stage

   Not phased

   Ages

   18 and older

   Site

   USC / Norris Comprehensive Cancer Center, Los Angeles, California

   Run by

   University of Southern California

   See if you can join NCT05786664 on ClinicalTrials.gov

2. Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

   This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in treating patients with breast cancer. Vaccines like WOKVAC are made from tumor-associated antigens which…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT04329065 on ClinicalTrials.gov

3. Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

   This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT06401889 on ClinicalTrials.gov

4. A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial

   This phase II trial tests the safety and effectiveness of a dietary supplement called resistant potato starch for reducing musculoskeletal symptoms in patients with stage 0-III breast cancer or who are at high risk for breast cancer and are planning to receive treatment with an aromatase inhibitor.…

   Stage

   Phase 2

   Ages

   Any age

   Site

   University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

   Run by

   University of Michigan Rogel Cancer Center

   See if you can join NCT07443943 on ClinicalTrials.gov

5. Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

   This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the gr…

   Stage

   Phase 2

   Ages

   65 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06042569 on ClinicalTrials.gov

6. Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

   This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly diagnosed breast cancer. Decision making tool may help patients with early stage breast cancer make decisions regarding their su…

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT02918474 on ClinicalTrials.gov

7. Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

   This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience…

   Stage

   Not phased

   Ages

   20 and older

   Site

   Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota

   Locations

   5 in total

   Run by

   Mayo Clinic

   See if you can join NCT05417867 on ClinicalTrials.gov

8. Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

   This early phase I trial studies the possible benefits and/or side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced q…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT05417308 on ClinicalTrials.gov

9. Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

   This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor positive (HR+) breast cancer. Aromatase inhibitors (AI) are medications…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Grady Health System, Atlanta, Georgia

   Locations

   4 in total

   Run by

   Emory University

   See if you can join NCT06534125 on ClinicalTrials.gov

10. Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

    This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating patients with triple negative breast cancer. This vaccine is made by ta…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Grady Health System, Atlanta, Georgia

    Locations

    4 in total

    Run by

    Emory University

    See if you can join NCT06324240 on ClinicalTrials.gov

11. The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

    This study is being done to learn more about breast cancer patients' experiences with sleep changes during cancer treatment, identify possible reasons for poor sleep quality, and to find out how stress, social support, and living environment affect sleep.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Ohio State University Comprehensive Cancer Center

    See if you can join NCT07341503 on ClinicalTrials.gov

12. Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

    The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other symptoms commonly experienced by women with newly diagnosed stage II-III triple negative breast canc…

    Stage

    Not phased

    Ages

    40 to 65

    Site

    Yale University, New Haven, Connecticut

    Locations

    2 in total

    Run by

    Ohio State University Comprehensive Cancer Center

    See if you can join NCT06582615 on ClinicalTrials.gov

13. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

    Locations

    963 in total

    Run by

    SWOG Cancer Research Network

    See if you can join NCT05929768 on ClinicalTrials.gov

14. Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

    This phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor positive triple-negative breast carcinoma. Standard therapy before surgery for triple-negative breast ca…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vandana Abramson

    See if you can join NCT07016399 on ClinicalTrials.gov

15. Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

    This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage breast cancer. BCT …

    Stage

    Phase 2

    Ages

    40 and older

    Site

    City of Hope at Arcadia, Arcadia, California

    Locations

    7 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06954831 on ClinicalTrials.gov